Graham Mullis - Novacyt CEO and Director
| ALNOV Stock | EUR 0.83 0.01 1.22% |
CEO
Mr. Graham D. Mullis was Chief Executive Officer, Executive Director and Member of the Executive Team of NOVACYT S.A. since June 13, 2014. He was Chief Executive Officer of Lab21 since 2008. He has over 30 years of experience in the healthcare, pharmaceuticals and medical device market. Over the years, he has led multiple exits, including that of Biocompatibles Eyecare, ClearLab, VisionTec and Optivue. He also founded a pharmaceutical licensing company called Optivue which focuses on repurposed drugs. Previous roles have included acting as a Clevel executive with Biocompatibles International plc, a FTSE 250 company, and 1800 CONTACTS, a NASDAQlisted company. He holds BS in Biochemistry Physiology from Southampton University, United Kingdom and an MBA from Warwick Business School, United Kingdom. since 2014.
| Age | 53 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 33 1 39 46 51 04 |
| Web | https://www.novacyt.com |
Novacyt Management Efficiency
The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt's management efficiency ratios could be used to measure how well Novacyt manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 |
Novacyt Leadership Team
Elected by the shareholders, the Novacyt's board of directors comprises two types of representatives: Novacyt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt's management team and ensure that shareholders' interests are well served. Novacyt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Heath, Non-Executive Director | ||
| Steve Gibson, Member of the Executive Team, Group Financial Controller | ||
| Jim Wicks, Member of the Executive Team, Managing Director Primer Design Division | ||
| Mandy Cowling, Member of the Executive Team, Corporate & Investor Relations Manager | ||
| Ian Wilde, Head of Quality Assurance and Regulatory Compliance | ||
| Eric Peltier, Chief Innovation Officer | ||
| David Franks, Chief Officer | ||
| Anthony Dyer, Fin. Director | ||
| James McCarthy, Acting CFO | ||
| James Wakefield, Independent Non-Executive Chairman | ||
| Bryan Close, Chief Officer | ||
| Paul Oladimeji, Group RD | ||
| Paul Eros, Member of the Executive Team, Managing Director Primerdesign Division | ||
| Aymeric Perchant, Research and Development Director | ||
| Bruce Kaufman, Independent Director | ||
| Edwin Snape, Independent Non-Executive Director | ||
| Graham Mullis, CEO and Director | ||
| JeanPierre Crinelli, Deputy CEO, Director | ||
| Grald Ulrich, Chief Devel | ||
| Ruth Powell, Member of the Executive Team, Managing Director NOVAprep Division | ||
| Juliet Thompson, Independent Non-Executive Director | ||
| Phillip Sefton, Member of the Executive Team, Managing Director Lab21 Division | ||
| Wendy Karban, Member of the Executive Team, Group Human Resource Manager | ||
| Alan Howard, Non-Executive Director |
Novacyt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novacyt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (48.03 M) | |||
| Shares Outstanding | 70.63 M | |||
| Shares Owned By Insiders | 3.49 % | |||
| Shares Owned By Institutions | 1.60 % | |||
| Price To Earning | (1.71) X | |||
| Price To Book | 0.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novacyt in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novacyt's short interest history, or implied volatility extrapolated from Novacyt options trading.
Pair Trading with Novacyt
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novacyt position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novacyt will appreciate offsetting losses from the drop in the long position's value.Moving against Novacyt Stock
| 0.48 | GDS | Ramsay Generale De | PairCorr |
| 0.46 | GALIM | Galimmo SA | PairCorr |
The ability to find closely correlated positions to Novacyt could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novacyt when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novacyt - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novacyt to buy it.
The correlation of Novacyt is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novacyt moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novacyt moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novacyt can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Novacyt. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Novacyt Stock analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |